Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.63 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149738 | 0.95 | MAPT (0.66) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL29171445 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL29171439 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL29171438 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL29171402 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL14930509 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL9307505 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL29171419 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL29171407 | 0.94 | SMPD1 (0.67) | MAPTPRSS1SMPD1TSHRMGLL | |
| SCHEMBL18089529 | 0.94 | MAPT (0.57) | MAPTPRSS1SMPD1TSHRMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323991-A1 | PBD CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200289659-A1 | CONJUGATES FOR TREATING DISEASES | ENDOCYTE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10624972-B2 | Conjugates for treating diseases | ENDOCYTE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200038514-A1 | FOLATE CONJUGATE FOR USE IN TARGETING TUMOR ASSOCIATED MACROPHAGES | ENDOCYTE INC (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2017172930-A1 | PBD CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2016148674-A1 | CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-7265105-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| EP-1413582-B1 | Dimeric pyrrolobenzodiazepines | SPIROGEN LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624972-B2 | Conjugates for treating diseases | CD79B, MALT1, TPMT | MAPT 1077/4885PRSS1 3103/4885SMPD1 64/4885 |
| US-20200289659-A1 | CONJUGATES FOR TREATING DISEASES | CD79B, MALT1, TPMT | MAPT 1077/4885PRSS1 3103/4885SMPD1 64/4885 |
| US-20200038514-A1 | FOLATE CONJUGATE FOR USE IN TARGETING TUMOR ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | MAPT 3243/4885PRSS1 1748/4885SMPD1 771/4885 |
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | MAPT 2734/4885PRSS1 4642/4885SMPD1 4840/4885 |
| US-20200323991-A1 | PBD CONJUGATES FOR TREATING DISEASES | CD79B, BTD, PBDC1 | MAPT 753/4885PRSS1 3469/4885SMPD1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.